Janssen (JNJ) Submits Biologics License Application (BLA) to the FDA for Guselkumab in Treatment of Adults with Moderate-to-Severe Plaque Psoriasis

Source Link:

http://www.prnewswire.com/news-releases/janssen-submits-application-to-fda-seeking-approval-of-anti-interleukin-23-monoclonal-antibody-guselkumab-for-the-treatment-of-moderate-to-severe-plaque-psoriasis-300365063.html